BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hoffmann-vold A, Fretheim H, Halse A, Seip M, Bitter H, Wallenius M, Garen T, Salberg A, Brunborg C, Midtvedt Ø, Lund MB, Aaløkken TM, Molberg Ø. Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort. Am J Respir Crit Care Med 2019;200:1258-66. [DOI: 10.1164/rccm.201903-0486oc] [Cited by in Crossref: 55] [Cited by in F6Publishing: 73] [Article Influence: 18.3] [Reference Citation Analysis]
Number Citing Articles
1 Allanore Y, Vonk MC, Distler O, Azuma A, Mayes MD, Gahlemann M, James A, Kohlbrenner V, Alves M, Khanna D, Highland KB; SENSCIS-ON trial investigators. Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON. Ann Rheum Dis 2022:annrheumdis-2022-222564. [PMID: 35973804 DOI: 10.1136/ard-2022-222564] [Reference Citation Analysis]
2 Assassi S, Shao N, Yin Z, Volkmann ER, Zoz DF, Leonard TB. Understanding diagnostic pathways in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: A retrospective cohort study. Medicine (Baltimore) 2022;101:e29993. [PMID: 35960051 DOI: 10.1097/MD.0000000000029993] [Reference Citation Analysis]
3 Lafyatis R, Valenzi E. Assessment of disease outcome measures in systemic sclerosis. Nat Rev Rheumatol 2022. [PMID: 35859133 DOI: 10.1038/s41584-022-00803-6] [Reference Citation Analysis]
4 Hoffmann-Vold AM, Distler O, Crestani B, Antoniou KM. Recent advances in the management of systemic sclerosis-associated interstitial lung disease. Curr Opin Pulm Med 2022. [PMID: 35855572 DOI: 10.1097/MCP.0000000000000901] [Reference Citation Analysis]
5 Assassi S, Distler O, Allanore Y, Ogura T, Varga J, Vettori S, Crestani B, Voss F, Alves M, Stowasser S, Maher TM; SENSCIS trial investigators. Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial. ACR Open Rheumatol 2022. [PMID: 35852465 DOI: 10.1002/acr2.11483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Maher TM, Bourdin A, Volkmann ER, Vettori S, Distler JHW, Alves M, Stock C, Distler O. Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects. Respir Res 2022;23:178. [PMID: 35790961 DOI: 10.1186/s12931-022-02095-6] [Reference Citation Analysis]
7 Matteson EL, Kelly C, Distler JHW, Hoffmann-Vold AM, Seibold JR, Mittoo S, Dellaripa PF, Aringer M, Pope J, Distler O, James A, Schlenker-Herceg R, Stowasser S, Quaresma M, Flaherty KR; INBUILD Trial Investigators. Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial. Arthritis Rheumatol 2022;74:1039-47. [PMID: 35199968 DOI: 10.1002/art.42075] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Bonella F, Cottin V, Valenzuela C, Wijsenbeek M, Voss F, Rohr KB, Stowasser S, Maher TM. Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases. Adv Ther 2022. [PMID: 35576048 DOI: 10.1007/s12325-022-02145-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Parfrey H. The hidden costs of living with systemic sclerosis-associated interstitial lung disease. Respirology 2022. [PMID: 35538640 DOI: 10.1111/resp.14275] [Reference Citation Analysis]
10 Khanna SA, Nance JW, Suliman SA. Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis. Curr Rheumatol Rep 2022;24:166-73. [PMID: 35499699 DOI: 10.1007/s11926-022-01067-5] [Reference Citation Analysis]
11 Bernstein EJ, Assassi S, Castelino FV, Chung L, Correia C, Evnin LB, Frech TM, Gordon JK, Skaug BA, Hant FN, Hummers LK, Sandorfi N, Shah AA, Shanmugam VK, Steen VD, Khanna D. Computed Tomography of the Chest to Screen for Interstitial Lung Disease in Patients With Systemic Sclerosis at Expert Scleroderma Centers in the United States. ACR Open Rheumatol 2022. [PMID: 35460213 DOI: 10.1002/acr2.11434] [Reference Citation Analysis]
12 Tennøe AH, Murbræch K, Didriksen H, Ueland T, Palchevskiy V, Weigt SS, Fretheim H, Midtvedt Ø, Garen T, Brunborg C, Aukrust P, Molberg Ø, Belperio JA, Hoffmann-Vold AM. Serum markers of cardiac complications in a systemic sclerosis cohort. Sci Rep 2022;12:4661. [PMID: 35304587 DOI: 10.1038/s41598-022-08815-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Chen L, Zhu M, Lu H, Yang T, Li W, Zhang Y, Xie Q, Li Z, Wan H, Luo F. Quantitative evaluation of disease severity in connective tissue disease-associated interstitial lung disease by dual-energy computed tomography. Respir Res 2022;23. [DOI: 10.1186/s12931-022-01972-4] [Reference Citation Analysis]
14 Knarborg M, Løkke A, Hilberg O, Ibsen R, Sikjær MG. Direct and indirect costs of systemic sclerosis and associated interstitial lung disease: A nationwide population‐based cohort study. Respirology. [DOI: 10.1111/resp.14234] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Aragona CO, Versace AG, Ioppolo C, La Rosa D, Lauro R, Tringali MC, Tomeo S, Ferlazzo G, Roberts WN, Bitto A, Irrera N, Bagnato G. Emerging Evidence and Treatment Perspectives from Randomized Clinical Trials in Systemic Sclerosis: Focus on Interstitial Lung Disease. Biomedicines 2022;10:504. [PMID: 35203713 DOI: 10.3390/biomedicines10020504] [Reference Citation Analysis]
16 Boleto G, Avouac J, Allanore Y. The role of antifibrotic therapies in the treatment of systemic sclerosis–associated interstitial lung disease. Therapeutic Advances in Musculoskeletal 2022;14:1759720X2110666. [DOI: 10.1177/1759720x211066686] [Reference Citation Analysis]
17 Khanna D, Distler O, Cottin V, Brown KK, Chung L, Goldin JG, Matteson EL, Kazerooni EA, Walsh SL, Mcnitt-gray M, Maher TM. Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography. Journal of Scleroderma and Related Disorders. [DOI: 10.1177/23971983211064463] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Hilberg O, Hoffmann-vold A, Smith V, Bouros D, Kilpeläinen M, Guiot J, Morais A, Clemente S, Daniil Z, Papakosta D, Fretheim H, Neves S, Alfaro TM, Antoniou KM, Valveny N, Asijee G, Soulard S, Wuyts W. Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries. ERJ Open Res 2022;8:00597-2021. [DOI: 10.1183/23120541.00597-2021] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
19 Ruaro B, Baratella E, Confalonieri P, Wade B, Marrocchio C, Geri P, Busca A, Pozzan R, Andrisano AG, Cova MA, Confalonieri M, Salton F. High-Resolution Computed Tomography: Lights and Shadows in Improving Care for SSc-ILD Patients. Diagnostics (Basel) 2021;11:1960. [PMID: 34829307 DOI: 10.3390/diagnostics11111960] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
20 Hyldgaard C, Bendstrup E, Pedersen AB, Pedersen L, Ellingsen T. Interstitial Lung Disease in Connective Tissue Diseases: Survival Patterns in a Population-Based Cohort. J Clin Med 2021;10:4830. [PMID: 34768349 DOI: 10.3390/jcm10214830] [Reference Citation Analysis]
21 Syed Gaggatur N, Sange AH, Srinivas N, Sarnaik MK, Modi S, Pisipati Y, Vaidya S, Sange I. Systemic Sclerosis: Highlighting Respiratory Complications and Significance of Early Screening. Cureus 2021;13:e17291. [PMID: 34552830 DOI: 10.7759/cureus.17291] [Reference Citation Analysis]
22 Cottin V, Larrieu S, Boussel L, Si-Mohamed S, Bazin F, Marque S, Massol J, Thivolet-Bejui F, Chalabreysse L, Maucort-Boulch D, Jouneau S, Hachulla E, Chollet J, Nasser M. Epidemiology, Mortality and Healthcare Resource Utilization Associated With Systemic Sclerosis-Associated Interstitial Lung Disease in France. Front Med (Lausanne) 2021;8:699532. [PMID: 34552943 DOI: 10.3389/fmed.2021.699532] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Schneider U, Siegert E, Gläser S, Krüger K, Krause A; die Kommission Pharmakotherapie der DGRh. [Importance of mycophenolate mofetil for treatment of interstitial lung disease in systemic sclerosis]. Z Rheumatol 2021;80:868-78. [PMID: 34545432 DOI: 10.1007/s00393-021-01088-y] [Reference Citation Analysis]
24 Buschulte K, Hoffmann-Vold AM, Dobrota RD, Höger P, Krause A, Kreuter M. [Treatment of lung fibrosis in systemic rheumatic diseases (new treatment)]. Z Rheumatol 2021;80:743-54. [PMID: 34505934 DOI: 10.1007/s00393-021-01067-3] [Reference Citation Analysis]
25 Nambiar AM, Walker CM, Sparks JA. Monitoring and management of fibrosing interstitial lung diseases: a narrative review for practicing clinicians. Ther Adv Respir Dis 2021;15:17534666211039771. [PMID: 34477452 DOI: 10.1177/17534666211039771] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
26 Panagopoulos P, Goules A, Hoffmann-Vold AM, Matteson EL, Tzioufas A. Natural history and screening of interstitial lung disease in systemic autoimmune rheumatic disorders. Ther Adv Musculoskelet Dis 2021;13:1759720X211037519. [PMID: 34471427 DOI: 10.1177/1759720X211037519] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Kase K, Watanabe S, Saeki K, Waseda Y, Takato H, Ichikawa Y, Murata A, Yasui M, Noriyuki O, Hara J, Sone T, Abo M, Kimura H, Kasahara K. Fractional analysis of bronchoalveolar lavage in systemic sclerosis-associated interstitial lung disease. J Thorac Dis 2021;13:4146-55. [PMID: 34422344 DOI: 10.21037/jtd-20-2596] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
28 Barisione G, Brusasco V. Pulmonary function tests in systemic sclerosis-associated interstitial lung disease: new directions and future prospects. Current Opinion in Physiology 2021;22:100442. [DOI: 10.1016/j.cophys.2021.05.005] [Reference Citation Analysis]
29 Podolanczuk AJ, Putman RK. Clinical Relevance and Management of "Pre-Interstitial Lung Disease". Clin Chest Med 2021;42:241-9. [PMID: 34024400 DOI: 10.1016/j.ccm.2021.03.009] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
30 Mattoo H, Pillai S. Idiopathic pulmonary fibrosis and systemic sclerosis: pathogenic mechanisms and therapeutic interventions. Cell Mol Life Sci 2021;78:5527-42. [PMID: 34145462 DOI: 10.1007/s00018-021-03874-y] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
31 Durheim MT, Hoffmann-Vold AM, Eagan TM, Hovden AO, Lund MB, Bjerke G, Birring SS, Jonassen TM, Johansen OE, Sjåheim T. ILD-specific health-related quality of life in systemic sclerosis-associated ILD compared with IPF. BMJ Open Respir Res 2020;7:e000598. [PMID: 32576559 DOI: 10.1136/bmjresp-2020-000598] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
32 Koslow M, Maleki-Fischbach M, Keith RC. Diagnosis and Management of Interstitial Lung Disease in Patients with Connective Tissue Diseases. Case Rep Rheumatol 2021;2021:6677353. [PMID: 33986967 DOI: 10.1155/2021/6677353] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Castelino FV, Moua T. Detection and Management of Interstitial Lung Diseases Associated With Connective Tissue Diseases. ACR Open Rheumatol 2021;3:295-304. [PMID: 33779080 DOI: 10.1002/acr2.11253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
34 Maher TM, Mayes MD, Kreuter M, Volkmann ER, Aringer M, Castellvi I, Cutolo M, Stock C, Schoof N, Alves M, Raghu G; SENSCIS Trial Investigators. Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol 2021;73:671-6. [PMID: 33142016 DOI: 10.1002/art.41576] [Cited by in Crossref: 2] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
35 Kreuter M, Ladner UM, Costabel U, Jonigk D, Heussel CP. The Diagnosis and Treatment of Pulmonary Fibrosis. Dtsch Arztebl Int 2021;118:arztebl. [PMID: 33531115 DOI: 10.3238/arztebl.m2021.0018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Hoffmann-Vold AM, Maher TM, Philpot EE, Ashrafzadeh A, Distler O. Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review. ERJ Open Res 2021;7:00235-2020. [PMID: 33644224 DOI: 10.1183/23120541.00235-2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Fretheim H, Halse AK, Seip M, Bitter H, Wallenius M, Garen T, Salberg A, Brunborg C, Midtvedt Ø, Molberg Ø, Hoffmann-Vold AM. Multidimensional tracking of phenotypes and organ involvement in a complete nationwide systemic sclerosis cohort. Rheumatology (Oxford) 2020;59:2920-9. [PMID: 32097470 DOI: 10.1093/rheumatology/keaa026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
38 Meier C, Freiburghaus K, Bovet C, Schniering J, Allanore Y, Distler O, Nakas C, Maurer B. Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease. Sci Rep 2020;10:21912. [PMID: 33318574 DOI: 10.1038/s41598-020-78951-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
39 Montesi SB, Fisher JH, Martinez FJ, Selman M, Pardo A, Johannson KA. Update in Interstitial Lung Disease 2019. Am J Respir Crit Care Med 2020;202:500-7. [PMID: 32412784 DOI: 10.1164/rccm.202002-0360UP] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
40 Johnson SR, Furst DE. Current Therapeutic Approaches in Scleroderma: Clinical Models of Effective Antifibrotic Therapies. Curr Treat Options in Rheum 2020;6:382-93. [DOI: 10.1007/s40674-020-00164-9] [Reference Citation Analysis]
41 Spagnolo P, Distler O, Ryerson CJ, Tzouvelekis A, Lee JS, Bonella F, Bouros D, Hoffmann-Vold AM, Crestani B, Matteson EL. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Ann Rheum Dis 2021;80:143-50. [PMID: 33037004 DOI: 10.1136/annrheumdis-2020-217230] [Cited by in Crossref: 14] [Cited by in F6Publishing: 43] [Article Influence: 7.0] [Reference Citation Analysis]
42 Hoffmann-Vold AM, Allanore Y, Alves M, Brunborg C, Airó P, Ananieva LP, Czirják L, Guiducci S, Hachulla E, Li M, Mihai C, Riemekasten G, Sfikakis PP, Kowal-Bielecka O, Riccardi A, Distler O; EUSTAR collaborators. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis 2021;80:219-27. [PMID: 32988845 DOI: 10.1136/annrheumdis-2020-217455] [Cited by in Crossref: 17] [Cited by in F6Publishing: 46] [Article Influence: 8.5] [Reference Citation Analysis]
43 Bernstein EJ, Jaafar S, Assassi S, Domsic RT, Frech TM, Gordon JK, Broderick RJ, Hant FN, Hinchcliff ME, Shah AA, Shanmugam VK, Steen VD, Khanna D. Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol 2020;72:1892-6. [PMID: 32583956 DOI: 10.1002/art.41415] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
44 Hoffmann-Vold AM, Allanore Y, Bendstrup E, Bruni C, Distler O, Maher TM, Wijsenbeek M, Kreuter M. The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease. Respir Res 2020;21:197. [PMID: 32703199 DOI: 10.1186/s12931-020-01459-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
45 Distler O, Assassi S, Cottin V, Cutolo M, Danoff SK, Denton CP, Distler JHW, Hoffmann-Vold AM, Johnson SR, Müller Ladner U, Smith V, Volkmann ER, Maher TM. Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur Respir J 2020;55:1902026. [PMID: 32079645 DOI: 10.1183/13993003.02026-2019] [Cited by in Crossref: 35] [Cited by in F6Publishing: 55] [Article Influence: 17.5] [Reference Citation Analysis]
46 Cheema TJ, Young M, Rabold E, Barbieri AN, Baldwin N, Steen VD. Patient and Physician Perspectives on Systemic Sclerosis-Associated Interstitial Lung Disease. Clin Med Insights Circ Respir Pulm Med 2020;14:1179548420913281. [PMID: 32214863 DOI: 10.1177/1179548420913281] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
47 Amjadi SS, Roofeh D, Namas R, Khanna D. Management of systemic sclerosis-associated interstitial lung disease in the current era. Int J Rheum Dis 2020;23:137-9. [PMID: 32043307 DOI: 10.1111/1756-185X.13799] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
48 Schniering J, Benešová M, Brunner M, Haller S, Cohrs S, Frauenfelder T, Vrugt B, Feghali-Bostwick C, Schibli R, Distler O, Müller C, Maurer B. 18F-AzaFol for Detection of Folate Receptor-β Positive Macrophages in Experimental Interstitial Lung Disease-A Proof-of-Concept Study. Front Immunol 2019;10:2724. [PMID: 31824505 DOI: 10.3389/fimmu.2019.02724] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
49 Keane MP. The Fibrosis Burden of Systemic Sclerosis. Am J Respir Crit Care Med 2019;200:1200-2. [PMID: 31390878 DOI: 10.1164/rccm.201907-1438ED] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
50 Hoffmann-Vold AM, Weigt SS, Saggar R, Palchevskiy V, Volkmann ER, Liang LL, Ross D, Ardehali A, Lynch JP 3rd, Belperio JA. Endotype-phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease. EBioMedicine 2019;50:379-86. [PMID: 31732480 DOI: 10.1016/j.ebiom.2019.10.050] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 5.7] [Reference Citation Analysis]